DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in... It is an experimental therapy that is being developed by NeoRx Corporation.
- Mechanism
- Curator reviewed
There are two important components of 166Ho-DOTMP. The first is DOTMP, a chemical that collects in bones. The other component of 166Ho-DOTMP is radioactive holmium, abbreviated 166Ho. 166Ho is a radioactive particle that is bound to the DOTMP. Certain types of cells in the body, such as many cancer cells, are sensitive to radioactivity and can be killed if they are close to a radioactive particle such as 166Ho. These properties make 166Ho-DOTMP a potentially useful drug for the treatment of cancers in the bone. When the drug collects in the bone, it will expose cells there to 166Ho, killing cancer cells.
- Primary indication
- Investigated for use/treatment in multiple myeloma.Curator reviewed
- Formula / weight
- C12H30HoN4O12P4 · 712.215 g/mol (avg)
- Also known as
- 166Ho-DOTMP · Chelating agent delivering Holmium-166 · Holmium Ho-166 DOTMP · Holmium-166 DOTMP
- Code names
- DOTMP HO-166
Resolves to
UOWMQDYQGKHTKV-IEOVAKBOSA-LSMILES[166Ho++].OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP([O-])([O-])=O)CCN(CP(O)(O)=O)CC1Which companies are running trials of DOTMP HO-166, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account